Yifan Pharmaceutical (002019) Quarterly Report Review: The inflection point of performance has reached a rapid growth rate that exceeds market expectations and the growth of the main pharmaceutical industry is driving volume
The 2024 quarterly report was released. The company achieved operating income of 1.3 billion yuan (+41.28% year-on-year, same below) and net profit to mother of 146 million yuan (+125.55%) in Q1 2024, after deducting net profit of non-attributable net profit1
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ
Wisdom Pharmaceutical (300149.SZ): Net loss of 254.606 million yuan in the first quarter
On April 26, Ge Longhui Pharmaceutical (300149.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 235 million yuan, a year-on-year decrease of 12.68%; net profit attributable to shareholders of listed companies - 254.606 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 28.00.94 million; basic earnings per share - 0.0509 yuan.
New Open Source (300109.SZ): Net profit of 121 million yuan in the first quarter increased 1.17% year over year
On April 26, Ge Longhui (300109.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 395 million yuan, up 8.73% year on year; net profit attributable to shareholders of listed companies was 121 million yuan, up 1.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 126 million yuan, up 6.21% year on year; basic earnings per share were 0.38 yuan.
Northeast Pharmaceutical (000597.SZ): Net profit of 576.33,900 yuan in the first quarter decreased 17.72% year-on-year
Gelonghui, April 26 | Northeast Pharmaceutical (000597.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1.94 billion yuan, down 17.58% year on year; net profit attributable to shareholders of listed companies was 576.339 million yuan, down 17.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 298.409 million yuan, down 32.96% year on year; basic earnings per share were 0.040 yuan
Kangchen Pharmaceutical (603590.SH): Net profit of 41.6543 million yuan in the first quarter increased 62.28% year-on-year
Gelonghui, April 25, 丨 Kangchen Pharmaceutical (603590.SH) released its report for the first quarter of 2024, achieving operating income of 199 million yuan, an increase of 20.67%; net profit attributable to shareholders of listed companies was 41.6543 million yuan, an increase of 62.28% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 39.6567 million yuan, an increase of 74.63% year on year; basic earnings per share were 0.27 yuan.